Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Injections of NNC0582-0001 in Healthy Adults

2023-506928-83-00 Protocol NN6582-4838 Human pharmacology (Phase I) - First administration to humans Ended

Start 12 Nov 2022 · End 16 Oct 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol NN6582-4838

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 56
Countries 1
Sites 1

Healthy Volunteers

Key facts

Sponsor
Novo Nordisk A/S
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
12 Nov 2022 → 16 Oct 2025
Decision date (initial)
2024-06-17
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2023-506928-83-00
EudraCT number
2022-001813-38
WHO UTN
U1111-1274-4316

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy Volunteers

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Novo Nordisk A/S

Sponsor organisation
Novo Nordisk A/S
Address
Novo Alle 1
City
Bagsvaerd
Postcode
2880
Country
Denmark

Scientific contact point

Organisation
Novo Nordisk A/S
Contact name
EU Submission Hub

Public contact point

Organisation
Novo Nordisk A/S
Contact name
EU Submission Hub

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Austria Ended 56 1
Rest of world 0

Investigational sites

Austria

1 site · Ended
Medical University Of Graz
N/A, Neue Stiftingtalstrasse 6, 8010, Graz

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Austria 2022-11-12 2025-10-16 2022-11-15 2024-10-26

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-05 Austria Acceptable with conditions
2024-05-12
2024-06-17
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-10-28 Austria Acceptable with conditions
2024-05-12
2024-10-28
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-01-20 Austria Acceptable with conditions
2024-05-12
2025-01-20